

CURRICULUM VITAE

KALUST UCAR, M.D.

PERSONAL DATA

Citizenship: U.S.A.

Business Address: Pacific Shores Medical Group
222 W. Eulalia Street, Suite #100-B,
Glendale, CA 91204
Phone: (818) 637-7611
Fax: (818) 637-5106

Pacific Shores Medical Group
1043 Elm Avenue, Suite #104,
Long Beach CA 90813
Phone: (562) 590-0345
Fax: (562) 437-8139

EDUCATION

Istanbul University, Istanbul Faculty of Medicine, 1975-1981, M.D.
Robert College, Istanbul, Turkey, 1971-1975, Majored in Sciences.

MEDICAL, WORK AND RESEARCH EXPERIENCE

July 2006 - Present:	GMHHC Community Advisory Board of Directors.
January 96 – Present:	Pacific Shores Medical Group.
Jan 98 – March 2005:	Associate Director of Clinical Research, GMH Comprehensive Cancer Center.
July 1998 – Present:	Clinical Assistant Professor of Medicine, UCLA.
July 1994 – Dec 1996:	Faculty, UCLA.
July 1991 – June 1994:	Fellow, Hematology-Oncology, UCLA.
June 1988 – June 1991:	Fellow, Endocrinology, SUNY at Buffalo.
Jan 1988 – June 1988:	Chief Resident, Department of Medicine, SUNY at Buffalo.
June 1985 – June 1988:	Intern & Resident, Department of Medicine, SUNY at Buffalo.
Apr 1984 – Apr 1985:	Research, Roswell Park Cancer Institute, Buffalo, NY.

HONORS & AWARDS

Fellow Teaching Award Nomination, UCLA, 1991-92, 1992-93.
Merit Scholarship: Medical School, 1975-1981, Robert College, 1971-1975.
Ranked in top 1% in nation-wide university entrance examination, 1975.
Ranked in top 1% in Field Medicine examinations, 1982.

BOARD CERTIFICATION & LICENSURE

Diplomat, American Board of Medical Oncology: 11/97, 118015.
Diplomat, American Board of Hematology: 11/96, 118015.
Diplomat, American Board of Internal Medicine: 118015, Sep 15, 1988.
California State License: A 049259. New York State License: 174675, Jun 24, 1988.
FLEX, ID#:560131017, June 1986. ECFMG, Standard Certificate: 334-240-9.

MEMBERSHIP IN PROFESSIONAL SOCIETIES

American College of Physicians.
American Society of Hematology (ASH Active Member ID # 128093).
American Society of Clinical Oncology (ASCO Active Member ID # 29967)
The Southwest Oncology group (SWOG): NCI Investigator # 23480 (12/21/94)

PUBLICATIONS

1. Raza A, Maheshwari Y, Ucar K, Mayers G, Preisler HD: "Proliferative Characteristics of Acute Nonlymphocytic Leukemia in Vivo". *Acta Haematologica (Basel)*, 77(3):140-145, 1987.
2. Ucar K, Durmaz R: "High Dose Chemotherapy Regimens". *Medical Hypothesis*, 19(2):101-102, 1986.
3. Raza A, Ucar K, Preisler HD, Mayers G: "In Vitro and in Vivo Assessment of Sensitivity to Ara-C in Myeloid Leukemias". *Seminars in Oncology*, 12(2) suppl 3(Jun):9-19, 1985.
4. Raza A, Ucar K, Preisler HD: "Double Labeling and In Vitro Versus in Vivo Incorporation of Bromodeoxyuridine in Patients with Acute Nonlymphocytic Leukemia". *Cytometry*, 6(6):633-640, Nov 1985.
5. Raza A, Spiridonidis C, Ucar K, Mayers G, Bankert R, Preisler HD: "Double Labeling of S-phase Murine Cells with Bromodeoxyuridine and a Second DNA Specific Probe". *Cancer Research*, 45(5):2283-2287, May 1985.
6. Raza A, Ucar K, Preisler HD: "In Vitro Labeling Index, 3Hara-C Incorporation and Inhibition of DNA Synthesis Versus Induction Outcome in AML Patients Treated with High Dose Ara-C". *Excerpta Medical*, 1985.
7. Raza A, Bhayana R, Ucar K, Kirshner J, Preisler HD: "Differences Between Labeling Index and DNA Histograms in Assessing S-phase Cells form a

- Homogeneous Group of Chronic Phase CML Patients”. *Cytometry*, 6(5):445-451, September 1985.
8. Raza A Ucar K, Bhayana R, Kempinski M, Preisler HD: “Utility and Sensitivity for anti-BrdU Antibodies in Assessing S-phase Cells Compared to Autoradiography”. *Cell Biochem Function*, 3(2):149-153, April 1985.
 9. Ucar, K. “The effects of histamine H2 receptor antagonists on melanogenesis and cellular proliferation in melanoma cells in culture”. *Biochemical and Biophysical Research Communications*, 177(1):545-550, 1991.
 10. Ucar, K., Ucar, R. “melanin synthesis does not preclude proliferative phenotype in B16 murine melanoma cell line”. (Manuscript in preparation).
 11. Ucar, K. “Silent’ pheochromocytoma presenting as acute abdomen, and review of literature: (Manuscript in preparation).
 12. Bick, RL, Ucar, K. “Hypercoagulability and thrombosis”. *Hematology Oncology Clinic North Am*, 6(6): 1421-1431, 1992
 13. Philip R, Brunette E, Kilinski L, Muruges D, McNally MA, Ucar K, Rosenblatt J, Okarma TB, Lebkowski JS. “Efficient and sustained gene expression in primary T lymphocytes and primary and cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes”. *Molec & Cellular Biol*, 14(4):2411-2418, Apr 1994
 14. Ucar K, Seeger RC, Challita PM, Watanabe CT, Yen TL, Morgan JP, Amado R, Chou E, McCallister T, Barber JR, Joily DJ, Reynolds cP, Gangaballi Ri, and Roseblatt JD. “Sustained Cytokine Production and Immunophenotypic Changes in Human Neuroblastoma Cell Lines Transduced with a Human Gamma Interferon Vector”. *Cancer Gene Therapy*, 2(3):171-181, 9/95.
 15. Ucar K, and Figlin R. Principles of Immunotherapy of Cancer. In Current Cancer Diagnosis and Treatment, Henderson c, Wilson C, Phillips T, Debas H, Northfelt D (eds). Appleton and Lange, Norwalk, CT, in press.
 16. Ucar R, Sanwo M, Ucar K, Beall G. “Interferons: their role in clinical practice: *Annals of Allergy, Asthma, & Immunology*, 75(5):377-386, 1995.

MEETING ABSTRACTS AND PRESENTATIONS

1. Raza A, Ucar K, block AMW, Larson R, Preisler HD, sandberg AA: “The Role of Cytogenetics in Determining Induction Outcome and remission duration of Patients with AML”. *Proc Am Assn Cancer Res*, 26:118, 1985 (Abstract).
2. Raza A, Ucar K, Islam A, Preisler HD: In Vivo BrdU and In Vitro 3HTdr to Study Cell Kinetics”. *Proc Ell Kinetics Society*, 1985 (Abstract).
3. Raza A, Ucar K, Preisler HD: “Quantitation of 3Hara-C Incorporation and DNA Synthesis from Individual Cells inHL-60 Tissue Culture Line “. *Proc Am Assn Cancer Res*, 26:1298, 1985 (Abstract).
4. Raza A, Islam K, Ucar K, Preisler HD: “Proliferative Characteristics of Leukemic Cells In Vivo in Patients with Acute and Chronic Leukemias”. *ASCO*, November 1985 (Abstract).

5. Raza A, Ucar K, Bhayana R, Preisler HD: "Simultaneous Detection for Two Probes Incorporated in the DNA by Combining Immunofluorescence and Autoradiography". American Society of Hematology, Blood 64:695, 1984 (Abstract).
6. Raza A, Ucar K, Zhao SC, Kuliczowski K, Preisler HD: "Relationship Between Nuclear Incorporation of Ara-C, Inhibition of DNA Synthesis and Induction Outcome in Patients with Acute Myeloid Leukemia Undergoing Therapy with High Dose Ara-C". American Society of Hematology, Blood 64(5):600, 1984 (Abstract).
7. Raza A, Ucar K, Preisler HD: "Quantitation of Ara-C Incorporation and DNA Synthesis in Individual Cells from Leukemic Patients". Kalamazoo. MI. 1984 (Abstract).
8. Raza A, Islam A, Ucar K, Preisler HD: "Relationship between Nuclear Incorporation of Ara-C; Inhibition of DNA Synthesis and Induction Outcome in Patients with AML Undergoing Therapy With High Dose Ara-C". American Society of Hematology, Blood 64(5):1-172A, 1084 (Abstract).
9. Ucar K, Ucar R. "H2 antagonists inhibit cellular proliferation in cultured melanoma cells" (oral presentation, AFRC National Meetings Seattle: Clinical Research, 39(2):356A, April 1991).
10. melanogenesis in cultured B16 melanoma cells". (poster presentation, AFRC National Meetings, Seattle: Clinical Research, 39(2):279A, April 1991).
11. Ucar, R., Ucar, K. "Melanin synthesis does not preclude cellular proliferation in B16 murine melanoma cells in culture". (Abstract, Pan-American Society for Pigment Cell Research, July 1991).
12. Ucar, K. "H2-anatgonists inhibit cellular proliferation in cultured B16 murine melanoma cells in a dose dependent manner". (Abstract, Pan-American Society for Pigment Cell Research July 1991).
13. Ucar, K, Arora, V.J., Ucar, R. "Role of tyrosine concentration on H2-antagonist effects in B16 melanoma cells". (Abstract, poster presentation, Proceedings, American Association for Cancer Research, 33:3142, March 1992).
14. Li, X, Kampe, C, Ucar, K, Stephens, D, Black, AC, Rosenblatt, J.D. "Gene therapy strategies for HIV-1 infection". (Abstract, First Annual UCLA AIDS Institute Symposium: Basic Sciences, 10/27/1992).
15. Ucar, K, Seeger, R.C., Reynolds, C.P., Kampe, C.E., Economou, J., Gangavalli, R., Barber, J. and Rosenblatt, J.D. "Phenotypic alterations in neuroblastoma cells following g-IFN transduction". Second International Conf on Gene Therapy of Cancer, San Diego, November 17, 1993 (poster presentation).
16. Ucar, K., Seeger, R.C., Reynolds, C.P., Kampe, C.E., Economou, J., Gangavalli, R., Barber, J., McCallister, T.J., Yen T, and Rsoenblatt, J.D. "g-IFN transduction results in phenotypic alterations in neuroblastoma cells". (poster, American Association for Cancer Research, San Francisco, CA, April 1994).
17. Kampe, CE, Miles, S, Ucar, K, Dubinett, S, Economou, J, and Rosenblatt, JD. "Enhancing immunogenicity of human Kaposi's sarcoma cells by gen

- transfer: The first example of B7 induction in a human tumor”. Abstract, UCLA AIDS Institute Symposium, January 11, 1994.
18. Shapter A, Ucar K, Martinez-Maza O, Toloza E, Farias-Eisner R, Rosenblatt J, Economou K, Berek JS “A murine ovarian teratocarcinoma cell line: Ex vivo growth and in vivo use as an animal model for gene therapy in ovarian carcinoma”. 27th Annual Society of Gynecologic Oncologists Mtg, February 11-14, 1996, New Orleans, Louisiana.
 19. Kalust Ucar, Amy DeBlaise-Kasai, Ghassan Al-Jazayrly, Mercedes Brenneisen, Gabriel Carabulea, Nerses S. Tchekmedyian, Glendale Memorial Hospital and Health Center, Glendale, CA, Mark Kozloff, Ingalls Health System Harvey, IL. Phase II study of weekly Trimetrexate (TMTX), 5-ASCO Proceedings, #1201, May, 2000.

RESEARCH GRANT SUPPORT

1. “Role of H2 Receptor Antagonists on Melanoma Cell Differentiation and Proliferation”. Glazo Inc., January-June, 1991
2. “Introduction of Cytokine Genes into Neuroblastoma Cells Using Retroviral Vectors and Liposomal Transfection”. Haddad/Concern Foundation fellowship in Tumor Immunology Award, January 1, 1994 - December 31, 1994.
3. “Enhancing Antigen Presentation in Human Neuroblastoma “. Jonsson Cancer Center Foundation, July 1, 1994 - June 30, 1995
4. “Enhancing Antigen Presentation in Human Neuroblastoma”. Cancer Research Coordinating Committee, January 1, 1995 - December 31, 1995.
5. “Investigator Initiated Study of Trimetrezate, 5FU and Leucovorin in Previously Treated and Untreated Patients with Metastatic or Recurrent Colorectal Cancer. US Bioscience, 4/98

CLINICAL TRIALS

1. Phase III study of Taxotere in Platinum Failure NSCLC Patients.
2. Gene Therapy of Human Neuroblastoma Utilizing gamma-IFN Transduced Cells.
3. Investigator Initiated Phase II Trial of Trimetrexate, 5FU and Leucovorin in Previously Treated and untreated Patients with Unresectable or Metastatic Colorectal Cancer. US Bioscience. 4/98.
4. A Phase II Trial of Trimetrexate Glucuronate, 5FU and Leucovorin in Patients with Locally Advanced or Metastatic Pancreatic Cancer. US Bioscience. 6/99.